Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDA Median Approval Times Still Rising, But What Does It Mean?

Executive Summary

First quarterly report of median US generic drug times shows longer time to approval than previous estimates, but that may not tell stakeholders much.
Advertisement

Related Content

Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says
ANDA Approvals May Be Hindered By New Elemental Impurities Requirements
GDUFA II Reviews Start Strong With High First-Cycle Approval Rate
New ANDA Review Pathways: Should You Be A Priority Or Expedited?
ANDA Approval Times Get Optimistic Estimate In Budget Request

Topics

Advertisement
UsernamePublicRestriction

Register

PS122756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel